Verve Therapeutics
VERV
Market cap $985M

11.03 USD

-0.03

0.27%

At close Jul 11, 4:00 PM EDT

After hours

11.05

+0.02

0.18%

1 day

-0.27%

5 days

-1.87%

1 month

72.61%

3 months

238.34%

6 months

100.55%

Year to date

83.53%

1 year

73.16%

5 years

-65.44%

10 years

-65.44%

About: Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Employees: 274

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

213% more call options, than puts

Call options by funds: $1.09M | Put options by funds: $348K

163% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 16

15% more funds holding

Funds holding: 166 [Q4 2024] → 191 (+25) [Q1 2025]

1.99% less ownership

Funds ownership: 92.92% [Q4 2024] → 90.92% (-1.99%) [Q1 2025]

16% less repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 64

17% less capital invested

Capital invested by funds: $444M [Q4 2024] → $369M (-$74.7M) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

0%

upside

Avg. target

$14.50

31%

upside

High target

$24

118%

upside

6 analyst ratings

1 positive

17%

5 neutral

83%

0 negative

0%

BMO Capital Kostas Biliouris	22%upside $13.50	Market Perform Downgraded	27 Jun 2025
HC Wainwright & Co. Mitchell Kapoor	22%upside $13.50	Neutral Downgraded	18 Jun 2025
LifeSci Capital Cory Jubinville	9%upside $12	Market Perform Downgraded	18 Jun 2025
Jefferies Roger Song	0%downside $11	Hold Downgraded	18 Jun 2025
Canaccord Genuity Whitney Ijem	18%upside $13	Hold Downgraded	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 20 articles about VERV published over the past 30 days

The Motley Fool

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program, VERVE-102.

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verve Therapeutics, Inc. (NASDAQ: VERV ) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Is it a fair deal?

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00.

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Zacks Investment Research

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Zacks Investment Research

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

CNBC Television

Lilly to buy gene-editing partner Verve for $1.3 billion

CNBC's Angelica Peebles reports on the latest news surrounding Eli Lilly.

Lilly to buy gene-editing partner Verve for $1.3 billion

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Halper Sadeh encourag.

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

The Motley Fool

Why Verve Therapeutics Stock Is Skyrocketing Today

Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.

Why Verve Therapeutics Stock Is Skyrocketing Today

JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV

Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers.

JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV

Schaeffers Research

Biotech Stock Surging on Billion-Dollar Buyout

Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly (LLY) will buy the company for $10.50 per share, or roughly $1.3 billion.

Biotech Stock Surging on Billion-Dollar Buyout

See News Rankings

Charts implemented using Lightweight Charts™